Protalix BioTherapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $16.50M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $2.94M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $8.84M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $14.43M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $16.50M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $2.94M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $8.84M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $14.43M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $9.44M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $4.67M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $2.91M 10-K · filed 2026-03-18 |
| 2024-09-30 | $2.19M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $10.13M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $3.76M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $5.27M 10-K · filed 2025-03-17 |
| 2023-09-30 | $8.94M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $4.05M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.30M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $4.59M 10-K · filed 2024-03-14 |
| 2022-09-30 | $8.65M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $2.02M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $5.91M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $3.44M 10-K · filed 2023-02-27 |
| 2021-09-30 | $5.56M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $2.33M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $4.60M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $2.00M 10-K · filed 2022-03-31 |
| 2020-09-30 | $3.15M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $5.26M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $8.88M 10-Q · filed 2020-06-01 |
| 2019-12-31 | $4.70M 10-K · filed 2021-03-30 |
| 2019-09-30 | $8.72M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $7.26M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $8.56M 10-Q · filed 2019-05-06 |
| 2018-12-31 | $4.73M 10-K · filed 2020-03-12 |
| 2018-09-30 | $4.89M 10-Q · filed 2019-03-18 |
| 2018-06-30 | $5.25M 10-Q · filed 2019-03-18 |
| 2018-03-31 | $4.76M 10-Q · filed 2019-03-18 |
| 2017-12-31 | $1.72M 10-Q · filed 2019-03-18 |
| 2017-09-30 | $7.29M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $3.00M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $2.74M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $693.00K 10-K · filed 2018-03-06 |
| 2016-09-30 | $2.10M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $1.49M 10-Q · filed 2016-08-08 |
| 2015-12-31 | $0.00 10-Q · filed 2016-11-09 |
| 2015-09-30 | $4.57M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $1.94M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $1.82M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $1.88M 10-Q · filed 2015-11-09 |
| 2014-09-30 | $1.99M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $2.10M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $1.74M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $2.09M 10-K · filed 2015-03-12 |
| 2013-09-30 | $2.05M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $2.03M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $1.70M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $1.41M 10-K · filed 2014-03-13 |
| 2012-09-30 | $4.03M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $1.54M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $815.00K 10-Q · filed 2012-05-09 |
| 2011-12-31 | $1.37M 10-K · filed 2013-02-28 |
| 2011-09-30 | $2.28M 10-Q · filed 2011-11-07 |
| 2011-06-30 | $1.72M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $7.01M 10-K · filed 2012-02-27 |